This is a bonus weekend “quickie” for you, so it’s not a stock I’m going to go in depth on… but I thought you might want a few moments to think about it while the market’s not open.
The promise is absurd, here’s a taste of it from the top of the ad:
“ALERT: Agora Financial’s biggest prediction yet
“On February 14th a miracle announcement could give hope to millions… overturning three decades of stuck-in-the-mud research… and sending 1 microcap stock THROUGH THE ROOF…
‘Alzheimer’s Disease is Now Completely Treatable'”
That’s an extraordinarily bold prediction to make, but it’s also, frankly, a bit cruel — no, we are not going to hear that “Alzheimer’s Disease is Now Completely Treatable” on February 14. That’s a headline promise to get your attention, and, if we’re being charitable, a hope for the future.
And the financial prediction is equally nutty:
“The prediction? For the first-time ever, a true Alzheimer’s breakthrough could be just days away from being unveiled to the public… by an unknown, microcap company no one’s heard of. Based on a similar historical precedent, if this prediction is correct – and we’re nearly certain it is – it could result in a surge in company value of as much as $40 billion. Hard to imagine, but if that kind of sudden growth happens to the small cap company DETAILED BELOW, the result would be unprecedented:the largest two-day gain in stock market history.”
So what’s the actual stock? I said we’ll be quick, so I’m going to skip over a lot of the usual stuff… Ray Blanco calls their technology a “revolutionary ‘prion targeting’ protocol,” and these are the hints he drops about the company:
“A scientific breakthrough so advanced… so revolutionary… it’s now being recognized by the world’s leading brain researchers as apotential CURE for a disease they thought couldn’t be stopped
“It’s true. Including…
“Doctors at the Boston University School of Medicine, who published a detailed paper on the science behind this doctor’s research, concluding it ‘offers new hope to Alzheimer’s Disease patients and families.’
“The University of British Columbia, which has partnered with this doctor to bring this solution to Alzheimer’s patients as fast as possible.
“A panel of experts at the prestigious Alzheimer’s Association International Conference who recently reached a consensus confirming this theory.”
And he claims that there’s a February 14 announcement coming…
“On February 14, 2018, this doctor is going to gather the press at his companyheadquarters… stride up to the podium… and stun the world”
And that there has been a lot of insider buying…
“Just 11 men and women make up this company’s Senior Management Team and Board of Directors.
And would you believe over the last several months these 11 men and women… the doctor included… bought more than 10 million shares of the company?”
And “in the know” buying…
“… recently, the smartest, most connected insiders and biotech investors in the game loaded up on this one….
“Michael Bigger, the legendary scientist turned technology investor who made a name for himself with investments in Innovative Fibers, Netflix, Priceline, Amazon, and more. He recently snapped up saying…
‘This is a multi-billion dollar opportunity hiding in a dark alley… Never in my life have I seen a situation with such enormous potential and catalysts already at work… ‘
“Eden Rahim – who with annual returns that have put Warren Buffett to shame, you could consider the ‘Buffett of Biotech’- recently went all-in on this company, declaring…
Are you getting our free Daily Update
"reveal" emails? If not,
just click here...‘I’m in it because of some of the really important insights it has discovered into the mechanism of action of Alzheimer’s disease… [It has] a really favorable risk/reward proposition.’
“A group of venture capitalists who insisted their identities be kept private. They didn’t just dip their toes in. They bought 18.7 million shares.”
So who is it? This is, Thinkolator sez, the little Canadian biotech ProMIS Neurosciences (PMN in Toronto, ARFXF OTC in the US).
And I’m not going to dig deep into this one, I just want you to be able to start your thinking on it. The important “slow your roll” item I want to bring to your attention is that the lead drug for ProMIS, PMN310, is still Pre-Clinical. That means it hasn’t yet been tested in a human being — this is a promising drug that seems to target toxic oligomers in the lab, but hasn’t yet been tried in a person.
Human trials, starting with an FDA approval to begin Phase 1, which has not yet been applied for, are at least a year away. Their investor presentation indicates that they are on track to initiate clinical trials in 2019 and “provide potentially superior clinical data vs aducanumab in late 2021” from their Phase II trials.
So yes, the company will likely have a quarterly report around February 14, but the most aggressive thing likely from that is some update to their timeline for applying to start Phase 1 trials (the IND application) at some point over the next year or so, or, perhaps some optimistic commentary about partnering with a larger company.
Blanco got many of his gushing comments about this drug from a Streetwise compilation of reports, it appears, so you can see that here if you like… or review the company’s investor presentation here.
Just do remember, please, that Alzheimer’s Disease drugs that are in the lab or even in Phase 1 trials are by their very nature exciting and hopeful… it’s when they try them on lots of human beings that reality has hit for most of the drugs we’ve seen advanced in the past, either because of safety concerns or lack of efficacy. The stock jumped 50% on Friday just because of Blanco’s ad campaign, but it’s still a tiny $77 million R&D company.
They say they’re “pursuing a Nasdaq listing, likely in 2018,” which could also have a big impact on the stock… and would be accompanied, I would assume, by some substantial capital raising — perhaps very soon They’ve been living hand to mouth by selling shares to raise the cash they burn through each quarter for the past couple years, but if they actually move to clinical trials they’ll need a lot more money.
The FDA is focusing on getting Alzheimer’s Disease drugs developed, and they have laid out several ways to speed up the approval process for these drugs… but that doesn’t mean they’re going to green light a drug that literally tens of millions of people would beg their doctors for without some clear indication of safety and at least a little bit of efficacy, so the clinical trial process is not going to go away, it can just speed up a bit. Which, of course, is not the primary concern for this little company because their drug has not yet even reached the point of applying to begin clinical trials… so cool your jets, ignore the promise of becoming a millionaire by Summer, look it over, and let us know what you think with a comment below. Maybe it will be a great winner, I have no idea, there are a lot of steps in between and investor enthusiasm could easily send the stock soaring after that kind of wild promise is made by a large financial publisher… but they’re not going to announce that they’ve cured Alzheimer’s Disease next month.
Over to year, dear readers… want to convince us either pro or con on ProMIS? Have at it with a comment below.
P.S. This isn’t the first time Blanco’s attention has been poured on an Alzheimer’s Disease stock — back in 2015 his teaser ad promises of a breakthrough, similar in tone to this ad, helped Anavex (AVXL) go from $5 to $15 in a matter of a week or so, though it came sharply back down when the reality of long-term clinical trials hit the stock. AVXL was far more advanced, of course, they were in Phase 2 trials at the time.
We’ve pretty much broken the back of this one in the biotech threads. “Danger Will Robinson!”
Welcome back Doc, the stock market is just no fun without you.
Please send links to the biotech threads on this subject
We are in the process of building out a better indexing system for the various discussion threads — in the future that will be dependent on people entering the “Topic” for comments that they submit (from among the choices in the drop down menu below the comment entry field, you can just start typing to see if the topic is already in the system and matchable). That won’t apply to all past comments, but we are selectively going back and adding topic tags to some comments as interest arises, to save folks from difficult searches.
ProMIS now has a topic tag, and the most recent comments relating to it (that are tagged) will be on this page: https://www.stockgumshoe.com/tag/promis-neurosciences-pmn-to-arfxf/
The stock has not been the focus of any prior articles, but Dr. KSS did post a longer comment about it last Summer here: https://www.stockgumshoe.com/2016/08/ten-common-biotech-investing-mistakes/#comment-4894999
Idea maybe,
Yes
No
Maybe
Wait and see
Would make it easier to make better choices.
Questions would then come as why it was rated as such. Get right to the core questions
https://www.stockgumshoe.com/author/dr-kss-md-phd/
A safe strategy when it comes to any drug involving Alzheimer’s would be to short it or buy put options. Sadly, most Alzheimer’s drugs fail clinical trials.
One miracle drug is not going to solve what is a complex disease involving a number of bio challenges…more than 30, according to Dr. Dale Bredesen who has had amazing success in California over 30 years of research, demonstrating in documented clinical trials that his approach is helping people stabilize, partially recover or be cured.
His “Bredesen Protocol” involves a myriad of suspects in Alzheimers, including heavy metal toxicity. His work is well documented as googling will reveal.
My wife’s ex-husband lived with us for a year in 2016-7. He was 54 when he came down with early Alz. We did the full protocol with him, under an integrative doctor’s supervision. Unfortunately it did not reverse his symptoms. Now at 57, he is fairly advanced though lately has stabilized. We still give him some of the supplements.
he is now living near us with his daughter and boyfriend, and has full time care, which we didn’t as it was too expensive.
Our research made it clear to us why one drug is never going to solve the Alz. equation: it involves many variables and even then, at least for now, it can be hit or miss. There’s also the factor of “will to live” which we’re not sure was present in our case, as this is a man who routinely told his daughters when they were under 10 that he didn’t want to get very old because it was so physically unattractive and unpleasant what happens to the bodies of old people. You begin to get the idea what kind of person this is. We began to wonder just how negative the psychological aspect of his illness is.
Two very important things to consider are bad fats and sugar. Sugar causes glycation so the proteins don’t work properly, putting it simply. But fats are probably a bigger problem because we were sold a bill of goods with the margarine and Crisco lies/poison. The brain is mostly fat and a large part of that is cholesterol. You feed it bad fats and you have a bad brain. All vegetable oils and trans-fats need to be banned. They cause oxidative stress to the vascular system and brain. The trans fats add extra damage to the lipo-portein coating on HDL and LDL so cells in the brain can’t access the needed goods inside the LDL.
I believe there have been no clinical trials or peer reviewed studies to date of Bredesen’s protocol. He is, however, a respected, credible and accomplished doctor – not a crackpot in any way. Following his protocol will make you a healthy and likely happier person… And there may be a connection to Alzheimer’s in that.
It’s s shame that Blanco can’t be even remotely honest. Yes, it will be fantastic the day that Alzheimer’s is beaten, but February 14th of this year isn’t going to be that day. Unfortunately, I always equate anything that Blanco says with that big pile out behind the cow barn.
Yep, there is a very wide gulf separating “Alzheimer’s Disease is Now Completely Treatable”” and “could give hope to millions”. Shame on them.
Ray’s stock picks has my portfolio up 40% last year.
Disclaimer: I’m the largest shareholder in this company. I have no clue what the February 14th headline is.
The way to think about PMN310 is a drug similar to Aducanumab that binds to the Toxic Oligomers but doesn’t bind the fibril (plaque) which is the driver of the Aria-E side effect of Adu. Aducanumab binds to both the toxic oligomer and the plaque. PMN310 doesn’t bind to the monomer.
I’ll leave it at that given the size of my position. I had no clue this article was coming out yesterday and I have never talk to Blanco. I don’t know the guy.. I’m cited on the landing page because I wrote a blog post about it a long time ago.
Michael
Thanks for chiming in, Michael, I thought that name sounded familiar…
Mr Blanco may have his signals crossed. Another company with links to a potential Alzheimer’s drug has news due in litigation that’s set for Feb 14th. Kannalife and Isodiol International investor Marvin Washington is suing the US DEA for practicing medicine without a license. The lawsuit, Washington v Sessions, is up for hearing on a motion by AG Jeff Sessions to dismiss it so that DEA does not have to admit or deny the charges. Mr Washington bought the rights to US Patent 6,630,507 on a brain protection drug invented by 3 NIMH scientists, then hit a snag when trying to arrange FDA clinical trials. DEA would not let them make the raw material needed to make and test the drug. They researched where DEA got the authority to second-guess the FDA, found that there was a temporary authority that should have expired 44 years ago, and sued. Mr Sessions does not want to lose his powers in the case and will obviously appeal an unfavorable ruling. Mr Washington does not want to lose his patent rights in the case, and likely will also appeal an unfavorable ruling. I predict this case will end up in the Supreme Court sometime next year. Meanwhile, the fact that the DEA blocked development of an Alzheimer’s drug because it’s too dumb to know the damage it’s doing, will likely move a lot of stocks on Feb 14th, particularly the ones that took a hit 2 weeks ago when Jeff Sessions last made news on cannabis. Can anyone say, “You’re fired”?
That twat Sessions cost me ~10K on that stupid announcement! Which has almost no meaning in Canada here! Grrrr….
I’d love to hear Trump say “you’re fired” one more time at him.
I hope it IS a cbd-based wonder drug that proves the cure. GWPH could well lead the way to legitimizing cannabis based products out of Sessions dark age mentality. Been betting on it for a year. BTW if any of y’all are really serious investors, and gamblers, check out IMLFF pipeline as well.
Read or listen over an hour to Ray’s BS, then even though you have paid a membership fee in the first place, he just leads you on and on about all the money that will flow to you if you buy the stock shares he’s promoting for you. Now if you want the name of the company or stock it will cost you $2000 to get in. Maybe that will leave you with a couple hundred to put in. You cannot go for it if you don’t have a pile of cash to play with !
You can watch for the QTRLY $500 payment to pop up. If it doesn’t, you can call Agora for it.
A lot more affordable and you get the whole story!
I figured out who it was yesterday Travis, and when I saw it was pre-stage my immediate enthusiasm waned. However, if anyone is gonna find the cure for AD and ALS it IS this guy. He has been at it some 35 years and has won the prestigious Jonas Salk lifetime achievement lifetime award in this field. This Dr Neil Cashman and his newly public co. have proven that big pharma has been wrong and selling false hope for years to the victims of these diseases, his patented methods already have better results than any meds out there now, and I for one am gonna buy&hold a bunch at 25 cents a share…even if nothing happens til 2021.
Give Dr Cashman time! He has already shown that Big Pharma are the cruel ones. They have been selling useless meds to “treat” AD&ALS for years! I for one am gonna buy&hold this stock…even if nothing happens til 2021. Hear me now…and believe me later!
Sounds like the PITS to me — Pie In The Sky.
Despite the hyperbole, this company MAY be onto something. The approach I am taking is to buy, sell half at a double (hopefully) and then let it ride. Like any other interesting small cap.
Happy to see an insider speak up
drdave
I think Agora and all their staff might be good candidates for Alzheimer’s drug trials. I don’t like any of their styles of reeling in money to their coffers. They seem to forget that desperate people trying to save their loved ones , are looking for hope. It is very cruel to take advantage of them.
Agora has got to be the most audacious publisher. Fear mongering and click-bait don’t even begin to describe their sales tactics.
I made the mistake of subscribing to Agoura last year. They sent me a post card with a number to call if I don’t want an auto renewal on my credit card. Called it to cancel and it’s a sex chat line.
What was that number? LOL.
Unfortunately, I have a family member going thru early stages of this dreadful disease so I didn’t appreciate Ray’s claim that there is a cure, etc etc — wish there was, obviously, Just another example of “fake news” — right? IMO
Alzheimer’s is one of the most devastating diseases known to plague mankind. Better odds of cure with stem cell therapy, particularly with mesenchymal cells. Check out Dr. Neil Riordan in Panama and Texas. Early work is very promising .
A lot of supplement companies are pitching natural cures for aging issues. My mother is 92 and still sharp as a tack. Her secret? She swims three times a week even though she is legally blind.
My intent in commenting on ProMIS is not to make it look risible (I don’t question its sincerity in its approach and its belief in the authenticity of its work) but simply to caution investors and safeguard against capital losses.
I see several issues about its approach that are not necessarily problems unique to ProMIS:
(1) the amyloid hypothesis has serious deficits. Science cannot even answer why amyloid is elaborated, though we have made contentions in early commentaries about its origin.
(2) Two major theories of the ailment have gained considerable momentum: these would be the dampened synaptic transmission hypothesis and the RAGE receptor-driven neuroinflammation hypothesis. The Candida torulopsis hypothesis is strong but needs further testing by a clinical antimicrobial trial.
(3) people keep forgetting that monoclonal antibodies are possibly the worst reagents to be using to go after Alzheimers. They are being used as stoichiometric binding agents in pursuit of amyloid occupancy. But does this make sense? Satisfying establishment of the mere extent to which mAb’s, among the largest molecules the body sees, can cross the blood brain barrier is lacking. People also forget that IgG is complement-fixing, and thus evokes strong secondary inflammatory responses; ProMIS I admit is using an IgG4 that may have abated complement-inducing activities though I’d need to see data to be sure. But even if complement is not activated, there is the issue of Fc receptor binding after antigen engagement, and Fc receptors abound….on macrophages, other immune cells, even on platelets. Thereby CNS inflammation is further stoked. An anticalin would be vastly more ideal in pursuit of finding an anti-amyloid reagent, though I doubt any solution lies in the amyloid approach to things.
(4) no disease being pursued by biotech has a greater gulf between in vitro and in vivo investigative mechanisms; a cell culture model of AD that is genuinely relevant on all axes is impossible, and no definitive animal model exists. We cannot be invasive (ie, brain biopsies) in assessment of the histopathology, which radically alters itself upon death. A true solution may await further development of miniature CNS agglomerations ex vivo attained by 3-D bioprinting or by signalling of stem cells , along with tactics to replicate presence of an immune system.
(5) $CWBR has a mitochondrially elaborated peptide that reverses amyloid induced neurotoxicity and neuron paucity. The mechanism is only partly known but tends to undermine the amyloid hypothesis. Rather, I regard the best theory of AD is that it represents a local CNS diabetes with mitochondriopathy and failed constitutive mitochondrial peptide elaboration. Support of this model is amassing rapidly. I predict CohBar is on track to have a serious remedy for AD more so than any company in biotech, and this is based on non-privileged information albeit info the company has yet to present in a wide manner.
Above all else I certainly wish Michael Bigger good fortune in his investing pursuits and respect his considerable intelligence. I think it’s fair to assert here that Bigger may be aware of information that is not public and that being a sizable shareholder may have given him access, via an NDA, to data we cannot know that supported his decision to invest. And if so, I hope he wins and wins massively. His integrity, good attitude and kindness are unsurpassed and his cerebral horsepower formidable.
I’m not under an NDA with Promis and I don’t have any information that other investors do not have.
Dr KSS.. So you are a bona fided MD.. or else you know a lot of medical terms strung together to sound reasonable. Thx for your scientific comments.
Thank you for the detailed reply. I really appreciate your input and effort.
Lost big time on AVXL! Not interested in this. But can you tell us what the $0.70 cryptocurrency Jim Rickards teased us with this weekend (on Saturday, Jan. 20, 2018) is? And how to buy into it?
Stellar Lumens (XLM) appears to be a close match. You would need to buy some Etherium (ETH) from the likes of Coinbase first then trade it for XLM on an exchange like Binance. Then I would recommend transferring them to a hard wallet device to take it offline so that you hold the private keys and can’t suffer loss from a hacking of the exchange.
I believe that it is Biogen that remains on the ‘fast track’ for its Alzheimers drug . . . It should be only a relatively short amount of time yet to determine whether it will be marketable or fall to the wayside. Current test results look rather promising.
Aducanumab is the only drug that has shown meaningful AD efficacy to date. I believe it will be approved (I don’t have a position).
This morning’s press release:
Humanized PMN310 Shows Significantly Greater Binding to The Toxic Oligomer Fraction of Alzheimer
s Disease Brain Extract Compared to AducanumabTORONTO and CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced further results of its previously announced and ongoing preclinical program for Alzheimers disease (AD). ProMIS is pleased to announce that its lead product candidate for AD, PMN310, compared to aducanumab (Biogen) showed significantly greater binding to the neurotoxic oligomer-enriched fraction of amyloid beta (Abeta) in brain extract from eight confirmed AD brains.
Commenting on these results, ProMIS Executive Chairman, Eugene Williams, stated: “We set out to design an improved antibody inspired by the initial successful clinical results of aducanumab, announced in Dec 2014. We recently reported greater selectivity of PMN310 for Abeta oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab. ProMIS also recently announced that PMN310 shows a lack of binding to plaque in and around blood vessels in the brain, thereby supporting the potential for lower risk of brain swelling and possibility of higher dosing with PMN310.”
Williams continued, “We are pleased to announce further results supportive of a best in class profile for our lead AD program. In comparison to aducanumab, humanized PMN310 showed significantly greater binding to brain material from AD patients containing toxic Abeta oligomers, the root cause of disease. Affinity maturation of PMN310 is ongoing and may result in an even greater advantage with PMN310; we look forward to sharing these results in the coming months.”
Recent reports from the scientific literature1-5 indicate that small, low molecular weight Abeta oligomers, consisting of twelve strands of Abeta (dodecamers), four strands (tetramers) or two strands (dimers) of Abeta are the toxic oligomer form. To test the binding to these toxic oligomers by PMN310 and other Abeta-directed antibodies, ProMIS isolated the soluble low molecular weight (LMW) fraction of brain material from eight AD brains expected to contain dodecamers, tetramers and dimers. Binding by aducanumab, bapineuzumab and humanized PMN310 to the toxic oligomer fraction from these brains was assessed by surface plasmon resonance (SPR). The results showed greater binding of aducanumab to the toxic oligomer LMW fraction compared to bapineuzumab, in line with the greater therapeutic benefit of aducanumab. Importantly, PMN310 showed even greater binding (~1.5-2 fold) compared to aducanumab. The ability to selectively target LMW toxic Abeta oligomers without binding Abeta monomers (reduced efficacy) or plaque (increased risk of brain swelling, also called ARIA-E) is expected to allow for safe administration of higher effective doses and greater therapeutic potency.
SPR is a highly sensitive technique to detect binding interactions. In the SPR study outlined above, the test antibody therapeutics (bapineuzumab, aducanumab and humanized PMN310) were each immobilized on an SPR sensor chip. The AD brain extract containing the LMW toxic oligomers was then flowed over each of the chips and the amount of toxic oligomer extract bound by the test antibodies was measured.
Additional information can be found in the latest company slide presentation at http://www.promisneurosciences.com
References
Shankar, GM et al (2008) Amyloid- protein dimers isolated directly from Alzheimer
s brains impair synaptic plasticity and memory. Nat Med 14: 837-842s disease. Brain 136: 1383-1398.Jin, M et al (2011) Soluble amyloid -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. PNAS 108: 5819-5834
Cleary, JP et al (2005) Natural oligomers of the amyloid- protein specifically disrupt cognitive function. Nature Neuroscience 8: 79-84
Yang, T et al (2017) Large soluble oligomers of amyloid -protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosc 37: 152-163
Lesne, SE et al (2013) Brain amyloid- oligomers in ageing and Alzheimer
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer
s disease (AD) and amyotrophic lateral sclerosis (ALS). The Companys proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.For further information please consult the Company`s website at: http://www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
David Schull
Russo Partners/LLC
David.Schull@russopartnersllc.com
Tel. 858 717-2310
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein@promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences
My wife has had Alzheimers for 5 years. Currently she is on Namenda the only
drug she tolerates. She has had very little regression and she still knows me and is very happy. Never complains about anything. She will forget something in 5 seconds. If she has ice cream and you ask her seconds later she says no I did not have ice cream. However she knows my name and her name
and our daughters name. She knows a few of her sisters names. She loves to color and walks around with a book and colored pens. I know she will never get better but I have taken positions to make sure she will always have money for her care. What else can I do????
Have you investigated the effects of diet on her condition? Some useful links to explore at the bottom of this older post an a similar topic.
https://www.stockgumshoe.com/2017/11/whats-happening-on-the-alzheimersdementia-front/comment-page-1/#comment-4960037
I feel for you .My husband is 83 and has been diagnosed with dementia several years ago and sounds a lot like your wife except he does not color and isn’t always happy. He was never diagnosed with ALzheimers and his original brain scans were free of plaques but showed brain shrinkage. He also takes Namenda and the patch. HIs regression comes in giant drops. this year after Hurricane Irma, last year after his daughters illness. he knows me, our dog, and his daughter, a few others but not their names. He is profoundly deaf and wears hearing aids but although expensive not reliable. Football brings us together but after the superbowl we will have lost that so I understand that statement What else can I do??? So hard. My friend who lost her husband to ALz.last year said “Life with Dan with Alz. was better than life without him” makes you think. good luck and thank God you have the money it will take. My fear is I will die first. Others Keep things in perspective and cut back on the sugars.
Please watch “Bright Brains” on PBS by Dr. Amen.
Mr. Miller, you appear to be doing so many things right, as your wife is very happy!
May I suggest 2 more? If you haven’t already found it, you might want to read another thread: https://www.stockgumshoe.com/2017/11/whats-happening-on-the-alzheimersdementia-front/comment-page-1/#comments
If you have old family pictures, you (or another loved one) might enjoy going through them with her and preparing a scrap book. If the scrap book never gets made, that’s fine – there’s joy in the memories of looking and talking about the people and events in the pictures.
#AD #Tunes Another joy to parents/patients with Alzheimer’s Disease is playing/listening to their favorite #music. Some may be found here at Magical Music Mystery Mining https://www.stockgumshoe.com/2016/05/microblog-magical-music-mystery-mining/ or youtube, itunes, soundcloud, etc Exercise, yoga, meditation, painting, socializing, going shopping, swimming, etc. may be of tremendous assistance as well… . #Best2ALL!
My dad was diagnosed with Alzheimer’s when he was about 80. I didn’t live very close but would take him omega 3, a good B complex with methylcobalamin and methyltetrahydrofolate (not folic acid). When I was there and able to guide his eating and supplements he showed marked improvement. As someone else mentioned in another post small amounts of lithium in drinking water has been associated with better mental health. Diet is very complex and needs some tailoring to the individual but avoid ALL vegetable oils and sugar. Use coconut, peanut or cold processed non-hydrogenated palm oil. Vegetable oils are very easily oxidized and once in the body can cause an oxidative cascade. Vitamin E can help with oxidation in the blood but remember vitamin E is 8 vitamins not just alpha tocopherol.
I read an article on researchers at MIT who engineered mice with AH of the brain and by aiming light at certain intervals (optogenetics) directly at each neuron , thereby eliminating the AH effects. The scientists then duplicated the effects by having the mice stare at this same light delivered at the same intervals. Human trials are expected in the very near future. Different approach than chemicals. I’m hopeful; lost a cousin to AH last year who developed it one yr after retirement at 62 yrs . His wife was the caregiver for 11 years; needless to say, they both suffered. Yes, indeed, it will be miraculous if/when there is a cure.
The only authoritative/reliable source on treatment published as/of late 2017 is Dale E. Bredesen, M.D. book: The End of Alzheimer’s, publ. by Avery, Penguin Random House, 375 Hudson St. N.Y., NY 10014. ISBN 978073516204. 36 specific factors that together are the principle causes of the disease are clinically identified and specific treatments for each defined. Hundreds of patients suffering from early to mid-stage Alzheimer’s have had recoveries recorded, documented by a widely respected peer group. Also see David Perlmutter, M.D. and Sara Gottfried, M.D. NY Times best selling authors on this affliction. Any other claim that fails to include Bredesen’s protocols are doomed to failure. No single drug or treatment can correct 36 factors that add up to progressive cognitive decline and eventual Alzheimer’s.
I have relatives who had or have Alzheimer’s. The impact on their families were profoundly difficult.
Perhaps next to a cure, a method to mitigate or retard the progress is very important. PLease watch PBS series on Bright Minds by Dr. Amen.
Alzheimers IS treatable in early stages and perhaps mid stage depending on individual, genes, etc. Dr. Dale Bredesen (google him) and his team are having some success. Having diabetes which I have controlled for 35 yrs with diet alone means I can live a reasonable healthy life but I can never put one bite of food in my mouth that contributes to worsening the disease and I believe the same about AD. It is an unending task to eat whole foods not coming out of a box but I am still going at 84. this year. A friend who was diagnosed with AD years ago was recently found to have very low thyroid as the cause so all health issues need to be addressed and remedied as well as diabetes type 3.
Best to all,
Somewhatcautious
SomeWhatCautious and ignorant – For you to post this on the 3rd anniversary my dad became pure Spirit is a slap in the face. You might try matriculating at an AD unit, or visiting your local nursing homes, daily, for six years, plus; then perhaps take a course in etiquette and sensitivity training. Here’s to hoping you fine tune your skills. #Best2YOU
I am really sorry for your loss. I think you misunderstand. The coincidence of this posting and your loss is only chance not any intentional disrespect. You should try being a 24/7 caretaker at home for 8 years at an advanced age. None of it is easy. Faith and living in the day. Thanks to all who have offered suggestions. I certainly will try to watch the PBS and follow up. I know,diet is everything.
#ThankYOU Fran 🙂 , I am and have been for 12 years + ;- )
Check out #ZKSS’ biotech thread if you desire. We would certainly welcome awesome members, as yourself. 😉 https://www.stockgumshoe.com/author/dr-kss-md-phd/ And my small contributions to the #Gr8Gummunity > https://www.stockgumshoe.com/author/sogiam/ 🙂 which includes #AOZ #Best2ALL! 🙂
My father had what we thought was Alzheimer’s for ten years. We donated his body/brain to Alzheimer’s research and in return was given very detailed information and a very detailed death certificate (which was hugely beneficial when applying for a survivor’s benefit with the VA). Turns out his brain showed little plaque but blockages that where the primary contribution to his dementia. For most part cardiovascular. Please take care of your heart to ward off dementia. Issue with Alzheimer’s research is no way to really know what is causing it and if a drug has some benefit (other than observable benefit and testing) until can see brain at autopsy. Taking care of your cardiovascular health is important and Alzheimer’s patients would be contributing so much to research if they donate their brain for autopsy. Hard decision but in the end in felt good that my father contributed to scientific research.